Приказ основних података о документу

dc.creatorĐedović, Neda
dc.creatorStanisavljević, Suzana
dc.creatorJevtić, Bojan
dc.creatorMomčilović, Miljana
dc.creatorLavrnja, Irena
dc.creatorMiljković, Đorđe
dc.date.accessioned2017-11-23T11:04:52Z
dc.date.available2017-11-23T11:04:52Z
dc.date.issued2017
dc.identifier.urihttp://linkinghub.elsevier.com/retrieve/pii/S0753332217331694
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0753332217331694
dc.identifier.urihttp://ibiss-r.rcub.bg.ac.rs/123456789/2864
dc.description.abstractEthyl pyruvate is a redox analogue of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that ethyl pyruvate ameliorates experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. It affects encephalitogenic T cells and macrophages in vitro, as well as in lymph nodes draining the site of encephalitogenic immunization and within the central nervous system (CNS). Here, in vivo effects of ethyl pyruvate on EAE are thoroughly investigated in the CNS and within the gut associated lymphoid tissue. Ethyl pyruvate reduced infiltrates within the CNS and number of activated macrophages/microglia (ED1(+)/Iba1(+)) and proliferating astrocytes (GFAP(+)). Furthermore, it reduced expression of HMGB1 in activated macrophages/microglia. It also reduced number of activated T cells and antigen-presenting cells and expression of Th1/Th17-related molecules in mesenteric lymph nodes and Peyer's patches. These results contribute to our understanding of anti-encephalitogenic effects of ethyl pyruvate as they provide evidence of its effects within the CNS and imply that these effects are related to reduction of inflammatory immune response in gut associated lymphoid tissue.
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173035/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41014/RS//
dc.rightsclosedAccess
dc.sourceBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
dc.subjectExperimental autoimmune encephalomyelitis
dc.subjectEthyl pyruvate
dc.subjectHMGB1
dc.subjectGut associated lymphoid tissue
dc.subjectMultiple sclerosis
dc.subject.otherm22
dc.titleAnti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut.
dc.typearticle
dcterms.abstractЂедовић, Неда; Момчиловић, Миљана; Лаврња, Ирена; Јевтић, Бојан; Станисављевић, Сузана; Миљковић, Ђорђе;
dc.rights.holder© 2017 Elsevier Masson SAS
dc.citation.volume96
dc.description.otherBiomedicine & Pharmacotherapy (2017), 96: 78-85
dc.identifier.doi10.1016/j.biopha.2017.09.110
dc.identifier.pmid28965011
dc.citation.apaDjedović, N., Stanisavljevic, S., Jevtić, B., Momčilović, M., Lavrnja, I., & Miljković, D. (2017). Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut. Biomedicine & pharmacotherapy, 96, 78–85.
dc.citation.vancouverDjedović N, Stanisavljevic S, Jevtić B, Momčilović M, Lavrnja I, Miljković D. Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut. Biomed Pharmacother. 2017;96:78–85.
dc.citation.spage78
dc.citation.epage85


Документи

Thumbnail

Овај рад се појављује у следећим колекцијама

Приказ основних података о документу